Eledon Pharmaceuticals, Inc. (ELDN)

2.4100 +0.1100 (+4.78%) At close: 04:00PM EDT

Eledon Pharmaceuticals, Inc.

19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612
United States
(949) 238-8090
https://eledon.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David-Alexandre C. Gros M.D., Ph.D.	CEO & Non Independent Director	866.35k	N/A	1972
Dr. Steven N. Perrin Ph.D.	President, Chief Scientific Officer & Non Independent Director	634.15k	N/A	1966
Mr. Paul Sean Little	CFO & Principal Accounting Officer	622.04k	N/A	1965
Mr. John Herberger	Vice President of Technical Operations	N/A	N/A	N/A
Mr. Bryan E. Smith J.D.	General Counsel, Corporate Secretary & Chief Compliance Officer	377.14k	N/A	1980
Dr. David Hovland Ph.D.	Chief Regulatory Officer	N/A	N/A	N/A
Dr. Eliezer Katz F.A.C.S., FACS, M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Corporate governance

Eledon Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.